NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 127 filers reported holding NURIX THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,375,623 | -21.3% | 556,695 | 0.0% | 1.36% | -10.5% |
| Q2 2023 | $5,561,383 | +10.5% | 556,695 | -1.8% | 1.52% | +0.8% |
| Q1 2023 | $5,032,252 | -19.1% | 566,695 | 0.0% | 1.51% | -13.9% |
| Q4 2022 | $6,222,311 | -15.7% | 566,695 | 0.0% | 1.75% | -11.8% |
| Q3 2022 | $7,384,000 | +2.8% | 566,695 | 0.0% | 1.99% | +1.5% |
| Q2 2022 | $7,180,000 | -5.7% | 566,695 | +4.3% | 1.96% | -1.3% |
| Q1 2022 | $7,612,000 | -14.2% | 543,344 | +77.4% | 1.98% | -11.1% |
| Q4 2021 | $8,868,000 | -3.4% | 306,320 | 0.0% | 2.23% | -8.4% |
| Q3 2021 | $9,177,000 | +12.9% | 306,320 | 0.0% | 2.44% | +43.2% |
| Q2 2021 | $8,127,000 | -14.7% | 306,320 | 0.0% | 1.70% | -24.7% |
| Q1 2021 | $9,523,000 | – | 306,320 | – | 2.26% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |